{"d":{"__metadata":{"id":"https://ws.parlament.ch/OData.svc/Subject(ID=70830L,Language='DE')","uri":"https://ws.parlament.ch/OData.svc/Subject(ID=70830L,Language='DE')","type":"itsystems.Pd.DataServices.DataModel.Subject"},"Meetings":{"__metadata":{"id":"https://ws.parlament.ch/OData.svc/Meeting(ID=5201L,Language='DE')","uri":"https://ws.parlament.ch/OData.svc/Meeting(ID=5201L,Language='DE')","type":"itsystems.Pd.DataServices.DataModel.Meeting"},"Sessions":{"__deferred":{"uri":"https://ws.parlament.ch/OData.svc/Meeting(ID=5201L,Language='DE')/Sessions"}},"Subjects":{"__deferred":{"uri":"https://ws.parlament.ch/OData.svc/Meeting(ID=5201L,Language='DE')/Subjects"}},"ID":"5201","Language":"DE","MeetingNumber":11,"IdSession":5212,"SessionNumber":12,"SessionName":"Fr\u00fchjahrssession 2026","Council":1,"CouncilName":"Nationalrat","CouncilAbbreviation":"NR","Date":"\/Date(1773619200000)\/","Begin":"1430","Modified":"\/Date(1776247630025)\/","LegislativePeriodNumber":52,"PublicationStatus":"final","MeetingOrderText":"Elfte Sitzung","SortOrder":11,"Location":"N"},"SubjectsBusiness":{"results":[{"__metadata":{"id":"https://ws.parlament.ch/OData.svc/SubjectBusiness(BusinessNumber=20267249,IdSubject=70830L,Language='DE')","uri":"https://ws.parlament.ch/OData.svc/SubjectBusiness(BusinessNumber=20267249,IdSubject=70830L,Language='DE')","type":"itsystems.Pd.DataServices.DataModel.SubjectBusiness"},"Subjects":{"__deferred":{"uri":"https://ws.parlament.ch/OData.svc/SubjectBusiness(BusinessNumber=20267249,IdSubject=70830L,Language='DE')/Subjects"}},"Businesses":{"__deferred":{"uri":"https://ws.parlament.ch/OData.svc/SubjectBusiness(BusinessNumber=20267249,IdSubject=70830L,Language='DE')/Businesses"}},"IdSubject":"70830","BusinessNumber":20267249,"Language":"DE","BusinessShortNumber":"26.7249","Title":"26.7108 Folgefrage 1: ","SortOrder":1,"PublishedNotes":null,"Modified":"\/Date(1773391827700)\/","TitleDE":"Fragestunde.\nFrage B\u00fcrgi Roman.\n26.7108. Folgefrage 1","TitleFR":"Heure des questions.\nQuestion B\u00fcrgi Roman.\nQuestion compl\u00e9mentaire\nnum\u00e9ro 1 \u00e0 la question 26.7108","TitleIT":null},{"__metadata":{"id":"https://ws.parlament.ch/OData.svc/SubjectBusiness(BusinessNumber=20267250,IdSubject=70830L,Language='DE')","uri":"https://ws.parlament.ch/OData.svc/SubjectBusiness(BusinessNumber=20267250,IdSubject=70830L,Language='DE')","type":"itsystems.Pd.DataServices.DataModel.SubjectBusiness"},"Subjects":{"__deferred":{"uri":"https://ws.parlament.ch/OData.svc/SubjectBusiness(BusinessNumber=20267250,IdSubject=70830L,Language='DE')/Subjects"}},"Businesses":{"__deferred":{"uri":"https://ws.parlament.ch/OData.svc/SubjectBusiness(BusinessNumber=20267250,IdSubject=70830L,Language='DE')/Businesses"}},"IdSubject":"70830","BusinessNumber":20267250,"Language":"DE","BusinessShortNumber":"26.7250","Title":"26.7108 Folgefrage 2: ","SortOrder":2,"PublishedNotes":null,"Modified":"\/Date(1773391908023)\/","TitleDE":"Fragestunde.\nFrage B\u00fcrgi Roman.\n26.7108. Folgefrage 2","TitleFR":"Heure des questions.\nQuestion B\u00fcrgi Roman.\nQuestion compl\u00e9mentaire\nnum\u00e9ro 2 \u00e0 la question 26.7108","TitleIT":null}]},"Transcripts":{"results":[{"__metadata":{"id":"https://ws.parlament.ch/OData.svc/Transcript(ID=371797L,Language='DE')","uri":"https://ws.parlament.ch/OData.svc/Transcript(ID=371797L,Language='DE')","type":"itsystems.Pd.DataServices.DataModel.Transcript"},"Subjects":{"__deferred":{"uri":"https://ws.parlament.ch/OData.svc/Transcript(ID=371797L,Language='DE')/Subjects"}},"MembersCouncil":{"__deferred":{"uri":"https://ws.parlament.ch/OData.svc/Transcript(ID=371797L,Language='DE')/MembersCouncil"}},"Businesses":{"__deferred":{"uri":"https://ws.parlament.ch/OData.svc/Transcript(ID=371797L,Language='DE')/Businesses"}},"ID":"371797","Language":"DE","IdSubject":"70830","VoteId":null,"PersonNumber":4238,"Type":1,"Text":"<pd_text><p>Das Risiko einer Myokarditis nach einer mRNA-Impfung ist sehr gering. Eine im Fachjournal \"Vaccine\" publizierte Metaanalyse von 15 Fachartikeln best\u00e4tigt, dass die H\u00e4ufigkeit bei Jugendlichen zwischen 12 und 17 Jahren nicht h\u00f6her liegt als andere vergleichbare Referenzh\u00e4ufigkeiten. Der Krankheitsverlauf nach einer Impfung ist in den meisten F\u00e4llen mild und vor\u00fcbergehend, mit guter Erholung unter unterst\u00fctzender Therapie. Schwere Komplikationen oder Todesf\u00e4lle als Folge der Impfung sind sehr selten und nicht kausal belegt. Im Vergleich dazu birgt eine Covid-19-Infektion ein deutlich h\u00f6heres Risiko f\u00fcr eine Myokarditis oder andere Komplikationen.</p>\n</pd_text>","MeetingCouncilAbbreviation":"N","MeetingDate":"20260316","MeetingVerbalixOid":4144,"IdSession":"5212","SpeakerFirstName":"Elisabeth","SpeakerLastName":"Baume-Schneider","SpeakerFullName":"Baume-Schneider Elisabeth","SpeakerFunction":"BR-F","CouncilId":99,"CouncilName":"Bundesrat","CantonId":26,"CantonName":"Jura","CantonAbbreviation":"JU","ParlGroupName":null,"ParlGroupAbbreviation":null,"SortOrder":1,"Start":"\/Date(1773673927813)\/","End":"\/Date(1773673987333)\/","Function":"BR-F","DisplaySpeaker":true,"LanguageOfText":"DE","Modified":"\/Date(1790250099423)\/","StartTimeWithTimezone":"\/Date(1773673927813+0060)\/","EndTimeWithTimezone":"\/Date(1773673987333+0060)\/","VoteBusinessNumber":null,"VoteBusinessShortNumber":null,"VoteBusinessTitle":null}]},"ID":"70830","Language":"DE","IdMeeting":"5201","VerbalixOid":796984,"SortOrder":27,"Modified":"\/Date(1790250099416)\/"}}